Kura Investors

Investor Home

Corporate Profile
We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Our development programs target cancers with high unmet need, including head and neck, lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
Recent Newsmore >
04/19/17
Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
04/07/17
Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
04/05/17
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Kura Oncology Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.